Program
pirtobrutinib
Also written as “Pirtobrutinib”, “LOXO-305” and “[14C]-LOXO-305”.
Its studies are mostly in Leukemia, Lymphocytic, Chronic, B-Cell · Lymphoma, B-Cell · Purpura, Thrombocytopenic, Idiopathic · Lymphoma, Mantle-Cell · Renal Insufficiency, led by 3 companies.
Drug pagePirtobrutinib: every studyAll 65 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Eli Lillyits history only | 2811 open or running | phase 4since Mar 6, 2025 | Nov 6, 2018 | Oct 2027phase 3 · NCT05254743 |
| AstraZeneca | 10 open or running | phase 2since Jan 21, 2025 | Jan 21, 2025 | none ahead |
| Nurix Therapeuticsits history only | 11 open or running | phase 3since Mar 31, 2026 | Mar 31, 2026 | Oct 2029phase 3 · NCT07516093 |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of AstraZeneca only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.
- Jul 28, 2021Named pirtobrutinibINNProposed as its International Nonproprietary Name in WHO's List 125 · before, LOXO-305
- Jan 21, 2025First study: phase 2 study in Leukemia, Lymphocytic, Chronic, B-CellFirst studyNCT06839872
TargetBeta
“An orally available, selective, non-covalent Bruton's tyrosine kinase (BTK) inhibitor ”NCIt, by rule
“Tyrosine-protein kinase BTK inhibitor”ChEMBL 37, by rule
Other programs on BTK
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| ibrutinibrule | Johnson & Johnson | phase 4 | 78 |
| acalabrutinibrule | AstraZeneca | phase 4 | 55 |
| zanubrutinibrule | BeOne Medicines | phase 4 | 35 |
| ritlecitinibrule | Pfizer | phase 3 | 42 |
| orelabrutinibrule | InnoCare Pharma | phase 3 | 27 |
| rilzabrutinibrule | Sanofi | phase 3 | 23 |
| evobrutinibrule | Merck KGaA, Darmstadt, Germany | phase 3 | 20 |
| fenebrutinib | Hoffmann-La Roche | phase 3 | 18 |
| nemtabrutinib | Merck | phase 3 | 16 |
| rocbrutinibrule | Lupeng Pharmaceutical | phase 3 | 15 |
| tirabrutinibrule | Gilead Sciences | phase 3 | 13 |
| birelentinibrule | Dizal Pharmaceuticals | phase 3 | 12 |
Studies
The one study AstraZeneca leads. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT06839872Leukemia, Lymphocytic, Chronic, B-Cell | 2 | Withdrawn | Jul 28, 2028 | 0 |
How it is read
Names in the registry
- “Pirtobrutinib”, 26 entries
- “LOXO-305”, 3 entries
- “[14C]-LOXO-305”, 2 entries
Conditions, from the studies’ own filings
- Leukemia, Lymphocytic, Chronic, B-Cell, 11 studies
- Lymphoma, B-Cell, 2 studies
- Purpura, Thrombocytopenic, Idiopathic, 1 study
- Lymphoma, Mantle-Cell, 1 study
- Renal Insufficiency, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.